Chelsea M Magin1, Rhea M May1, Michael C Drinker1, Kevin H Cuevas2, Anthony B Brennan3, Shravanthi T Reddy1. 1. Sharklet Technologies, Inc., Aurora, CO, USA. 2. Rocky Mountain Ophthalmology and InSight Innovations, LLC, Golden, CO, USA. 3. Sharklet Technologies, Inc., Aurora, CO, USA ; Department of Materials Science & Engineering and J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, USA.
Abstract
PURPOSE: To evaluate the ability of Sharklet (SK) micropatterns to inhibit lens epithelial cell (LEC) migration. Sharklet Technologies, Inc. (STI) and InSight Innovations, LLC have proposed to develop a Sharklet-patterned protective membrane (PM) to be implanted in combination with a posterior chamber intraocular lens (IOL) to inhibit cellular migration across the posterior capsule, and thereby reduce rates of posterior capsular opacification (PCO). METHODS: A variety of STI micropatterns were evaluated versus smooth (SM) controls in a modified scratch wound assay for the ability to reduce or inhibit LEC migration. The best performing topography was selected, translated to a radial design, and applied to PM prototypes. The PM prototypes were tested in an in vitro PCO model for reduction of cell migration behind an IOL versus unpatterned prototypes and IOLs with no PM. In both assays, cell migration was analyzed with fluorescent microscopy. RESULTS: All SK micropatterns significantly reduced LEC migration compared with SM controls. Micropatterns that protruded from the surface reduced migration more than recessed features. The best performing micropattern reduced LEC coverage by 80%, P = 0.0001 (ANOVA, Tukey Test). Micropatterned PMs reduced LEC migration in a PCO model by 50%, P = 0.0005 (ANOVA, Tukey Test) compared with both IOLs with no PM and IOLs with SM PMs. CONCLUSIONS: Collectively, in vitro results indicate the implantation of micropatterned PMs in combination with posterior chamber IOLs could significantly reduce rates of clinically relevant PCO. This innovative technology is a globally accessible solution to high PCO rates. TRANSLATIONAL RELEVANCE: A novel IOL incorporating the SK micropattern in a membrane design surrounding the optic may help increase the success of cataract surgery by reducing secondary cataract, or PCO.
PURPOSE: To evaluate the ability of Sharklet (SK) micropatterns to inhibit lens epithelial cell (LEC) migration. Sharklet Technologies, Inc. (STI) and InSight Innovations, LLC have proposed to develop a Sharklet-patterned protective membrane (PM) to be implanted in combination with a posterior chamber intraocular lens (IOL) to inhibit cellular migration across the posterior capsule, and thereby reduce rates of posterior capsular opacification (PCO). METHODS: A variety of STI micropatterns were evaluated versus smooth (SM) controls in a modified scratch wound assay for the ability to reduce or inhibit LEC migration. The best performing topography was selected, translated to a radial design, and applied to PM prototypes. The PM prototypes were tested in an in vitro PCO model for reduction of cell migration behind an IOL versus unpatterned prototypes and IOLs with no PM. In both assays, cell migration was analyzed with fluorescent microscopy. RESULTS: All SK micropatterns significantly reduced LEC migration compared with SM controls. Micropatterns that protruded from the surface reduced migration more than recessed features. The best performing micropattern reduced LEC coverage by 80%, P = 0.0001 (ANOVA, Tukey Test). Micropatterned PMs reduced LEC migration in a PCO model by 50%, P = 0.0005 (ANOVA, Tukey Test) compared with both IOLs with no PM and IOLs with SM PMs. CONCLUSIONS: Collectively, in vitro results indicate the implantation of micropatterned PMs in combination with posterior chamber IOLs could significantly reduce rates of clinically relevant PCO. This innovative technology is a globally accessible solution to high PCO rates. TRANSLATIONAL RELEVANCE: A novel IOL incorporating the SK micropattern in a membrane design surrounding the optic may help increase the success of cataract surgery by reducing secondary cataract, or PCO.
Authors: Nan Xia; Charles K Thodeti; Tom P Hunt; Qiaobing Xu; Madelyn Ho; George M Whitesides; Robert Westervelt; Donald E Ingber Journal: FASEB J Date: 2008-01-07 Impact factor: 5.191
Authors: Chelsea M Magin; Dylan B Neale; Michael C Drinker; Bradley J Willenberg; Shravanthi T Reddy; Krista Md La Perle; Gregory S Schultz; Anthony B Brennan Journal: Exp Biol Med (Maywood) Date: 2016-03-31
Authors: Sahba Mobini; Cary A Kuliasha; Zachary A Siders; Nicole A Bohmann; Syed-Mustafa Jamal; Jack W Judy; Christine E Schmidt; Anthony B Brennan Journal: J Biomed Mater Res A Date: 2020-06-29 Impact factor: 4.396